Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 90,038,969 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 90,038,969 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 90,038,969 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 90,038,969 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 90,038,969 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 90,038,969 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 90,038,969 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 90,038,969 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 90,038,969 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 6, 2026.


SCHEDULE 13G



 
Frazier Life Sciences Public Fund, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:08/14/2026
 
FHMLSP, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:08/14/2026
 
FHMLSP, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:08/14/2026
 
Frazier Life Sciences XI, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:08/14/2026
 
FHMLS XI, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:08/14/2026
 
FHMLS XI, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:08/14/2026
 
Frazier Life Sciences XII, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:08/14/2026
 
FHMLS XII, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date:08/14/2026
 
FHMLS XII, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XII, L.L.C.
Date:08/14/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

JOINT FILING AGREEMENT